Goodwin Advises Royalty Pharma on Transactional and Intellectual Property Aspects of Royalty Stream Purchase From AstraZeneca
The Life Sciences team advised transactional and intellectual property (IP) aspects of Royalty Pharma’s acquisition of a royalty in Zoryve from AstraZeneca for $100 million upfront. Zoryve, marketed by Arcutis Biotherapeutics, is a topical phosphodiesterase type 4 (PDE4) inhibitor approved for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis.
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and nonprofits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly — directly when it when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.
The Goodwin deal team was led by Jacqueline Mercier, Samuel Beavers, Robert Crawford, and Alison Liou, with invaluable assistance from Barry Bazian and Alex Valenti, and the Goodwin IP team was led by Carl Morales, Srikanth Reddy, Xixi Sun, and Yingying Cai.
For more information on the deal, please read the announcement.